1. The emerging role of BLyS/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential.
- Author
-
Hu SZ, Yuan ZY, Zhang XX, Yu XJ, Ni HY, Sun SJ, Xu T, and Zhan HQ
- Subjects
- Humans, Animals, Molecular Targeted Therapy, Tumor Necrosis Factor Ligand Superfamily Member 13 metabolism, Tumor Necrosis Factor Ligand Superfamily Member 13 antagonists & inhibitors, Tumor Necrosis Factor Ligand Superfamily Member 13 immunology, Autoimmune Diseases immunology, Autoimmune Diseases drug therapy, Autoimmune Diseases therapy, B-Cell Activating Factor immunology, B-Cell Activating Factor metabolism, B-Cell Activating Factor antagonists & inhibitors, B-Lymphocytes immunology, B-Lymphocytes metabolism
- Abstract
Autoimmune diseases (AIDs) are common diseases in the world. Some cases are difficult to cure and can only delay the progression of the diseases. The B lymphocyte stimulator (BLyS)/a proliferation-inducing ligand (APRIL) plays an important role in B cell homeostasis, regulation of both innate and adaptive immune responses. After binding to their receptors, BLyS/APRIL primarily affects the survival and development of marginal, transitional, and mature B cells. Of note, elevated BLyS/APRIL is seen in many AIDs, such as systemic lupus erythematosus, rheumatoid arthritis, immunoglobulin A nephropathy, etc. Moreover, there is evidence that blocking these two cytokines can control the number of serum autoantibodies, promote the depletion of B lymphocytes, inhibit the activation of T cells and dendritic lymphocytes, and reduce inflammatory stress. Currently, some clinical studies are underway targeting BLyS/APRIL inhibitors for the treatment of AIDs. However, due to the scattered knowledge on the relationship between BLyS/APRIL and AIDs, it is necessary to sort out the existing data. Therefore, in this review, we describe the basic biological characteristics and functions of BLyS/APRIL in AIDs, summarize the potential clinical applications of related inhibitors, especially monoclonal antibodies and recombinant fusion proteins targeting BLyS/APRIL in AIDs, and also outline promising research directions., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF